Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
AADI Stock News and Mentions of Aadi Bioscience, Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Aadi Bioscience Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Aadi Bioscience, Inc. (AADI).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Aadi Bioscience stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Aadi Bioscience, Inc. (AADI)
April 3, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Is Aadi Bioscience ( AADI ) Stock Outpacing Its Medical Peers This Year?
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Is Aadi Bioscience ( AADI ) Outperforming Other Medical Stocks This Year?
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
March 17, 2024 (12:00) / "PR Newswire" (by Aadi Bioscience)
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology ( SGO )
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin ... PR ...
In Article Trend: Neutral
March 13, 2024 (13:05) / "Zacks Commentary" (by Zacks Equity Research)
Aadi Bioscience, Inc. ( AADI ) Reports Q4 Loss, Misses Revenue Estimates
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 10.45% and 2.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 13, 2024 (12:00) / "PR Newswire" (by Aadi Bioscience)
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track to complete enrollment by May.
In Article Trend: Neutral
March 11, 2024 (21:30) / "Zacks Commentary" (by Zacks Equity Research)
NGM Biopharmaceuticals ( NGM ) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 10.81% and 91.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 7, 2024 (14:20) / "Zacks Commentary" (by Zacks Equity Research)
Evogene ( EVGN ) Reports Q4 Loss, Misses Revenue Estimates
Evogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 4, 2024 (13:18) / "Zacks Commentary" (by Zacks Equity Research)
Ocuphire ( OCUP ) to Report Q4 Earnings: What's in the Cards?
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
In Article Trend: Neutral
March 4, 2024 (13:04) / "Benzinga" (by Avi Kapoor)
Why BioVie Shares Are Trading Lower By Around 42%; Here Are 20 Stocks Moving Premarket - Adial Pharmaceuticals ( NASDAQ:ADIL ) , Aadi Bioscience ( NASDAQ:AADI )
Shares of BioVie Inc. BIVI fell sharply in today's pre-market trading after the company reported pricing of public offering. BioVie shares dipped 41.8% to $1.10 in pre-market trading Here are some other stocks moving in pre-market trading. Ainos, Inc. AIMD gained 112.3% to $2.23 in pre-market ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:08) / "PR Newswire" (by Aadi Bioscience)
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the ... PR ...
In Article Trend: Neutral
February 29, 2024 (23:20) / "Zacks Commentary" (by Zacks Equity Research)
Ginkgo Bioworks Holdings, Inc. ( DNA ) Reports Q4 Loss, Misses Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 20.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website